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Abstract
Background: Neonatal hepatitis B vaccination program at birth has been implemented nationwide since 1992 in
China. However, current HBV prevalence status in blood donors has not been entirely examined, which may impact
HBV safety in blood donations as the vaccinees over 18 years old progressively become the majority population of
blood donors.
Methods: In this study, 569,145 blood donors were screened for HBsAg by rapid tests and enzyme immunoassays,
among them 475,538 blood samples with negative HBsAg were further screened for HBV DNA by nucleic acid
testing between 2005 and 2014 at Shenzhen blood center.
Results: An overall 2.3 % HBsAg prevalence was found in the blood donor population during the past 10 years (2.86 %
in 2005, 1.76 % in 2010, and 2.79 % in 2014, respectively). HBsAg seroconversion occurred in 0.37 % of repeat-donors.
When stratified by age, the prevalence of HBsAg was found significantly higher in younger donors age 18–25 years
(2.73 %) than in those 26–35 years (2.13 %), 36–45 years (2.03 %) and 46–58 years (1.71 %) (P < 0.001), unexpectedly
suggesting that younger donors remained at risk of chronic HBV infection. Assuming that donors aged 18–22 born
before or after 1992 were non-vaccinated and vaccinated, respectively, HBsAg prevalence was higher in first-time
donors born ≥1992 (3.9 %) than prior to 1992 (3.5 %, P = 0.005). The incidence of HBV infection in the 5-year period
examined was significantly lower in repeat-donors born ≥1992 (0.27 %) than prior to 1992 (0.6 %, P = 0.008). The yield
of HBV DNA+/HBsAg- donors was 1:3,302, including 1:4,486 occult infections and 1:43,231 window period infections.
Conclusion: Young blood donors born after implementation of universal HBV vaccination in China presented
higher prevalence of HBsAg but lower incidence of HBsAg seroconversion than older, presumed unvaccinated,
donors. HBV vaccine boosting for adolescents at 15–17 years old prior to reaching blood donor age might
help improve blood safety.
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Background
Hepatitis B virus (HBV) infection is a global threat to
human health, especially in developing countries with
high prevalence. Individuals with detectable surface anti-
gen at six months interval (HBsAg) are considered
carriers of HBV chronic infection. In China, the preva-
lence of chronic HBV carriers declined from 9.5 to 7.2 %
in the general population aged 1–59 years. In children
<5 years between 1992 and 2006 HBsAg prevalence was
1 % following nationwide implementation of universal
HBV vaccination at birth [1]. However, although HBV
vaccine compliance progressively increased between
1992 and 2000 from 30 to 76 % then stabilized up to
96 % in 2005, recent reports indicated an overall compli-
ance of >90 % in general populations <20 years of age cor-
responding to a significant decline in HBsAg prevalence
between 3.6 % below 20 and 10.2 % between 20 and
60 years of age [2, 3]. Screening of HBsAg in blood donors
massively decreased the risk of HBV transmission by
transfusion, but did not identify pre-seroconversion win-
dow period infection (WPI) [4]. In recent years, occult
HBV infection (OBI) was defined as an absence of detect-
able HBsAg in circulation but presence of HBV DNA in
blood or liver tissue [5]. Implementation of nucleic acid
testing (NAT) for HBV DNA detection yielded 1:1000-
1:20,000 donor OBI carriers [4]. However, a small number
of blood donors with low-level of HBV DNA load could
not be identified by current screening NAT due to insuffi-
cient sensitivity [6, 7].
Over the past decades, universal vaccination has led to
a 70–90 % decrease in chronic HBV carrier rates world-
wide [8], and has resulted in a substantial decline in
disease burden, hepatitis B-related morbidity and mor-
tality [9–11]. Since infant vaccination started nationwide
in 1992, HBV vaccinees are gradually becoming the
majority of blood donors in China and are expected to
significantly improve HBV safety in blood donations.
However, in a previous study, we reported cases of HBV
recovered, chronic and occult infections in vaccinated
blood donors [12]. The current trend of HBV infection
in the blood donor population has not been systematic-
ally analyzed. In this study, we conducted a comprehen-
sive survey and analysis of HBsAg screening results
during the past 10 years (2005 to 2014) in donors strati-
fied according to type, geographical origin, gender, age,
and assumed vaccination status.
Methods
Subjects and samples
Candidate blood donors who were recruited for giving
blood in Shenzhen between 2005 and 2014 were
enrolled in this study. All donors were voluntary and
non-remunerated. First-time blood donors were defined
as donors who gave blood for the first time, while
repeat-donors were defined as donors who donated
blood more than once at the Shenzhen blood center.
The donors born in Guangdong province were classified
as native donors, while the donors born in other prov-
inces were classified as donors of other origins. Blood
samples (sera or plasmas) were collected from blood
donors at the Shenzhen blood center or during mobile
collection within 20 km of the city center.
Serological testing
All candidate donors passed the pre-donation question-
naire and underwent rapid pre-donation testing for
HBsAg (dipsticks with colloidal gold strip method, Abon
Diagnostics, Hangzhou, China) and ALT (Roche Refle-
tron, Roche Diagnostics Gmbh, Mannhein, Germany) at
the blood collection sites. HBsAg reactive samples were
considered confirmed. After pre-donation testing, blood
was collected from the qualified donors, and samples
were further screened in parallel and duplicate with two
different HBsAg EIAs (Diasorin S.P.A.-UK Branch and
Xinchang Diagnostics, Xiamen, China), anti-HCV (Ortho
Clinical Diagnostics, UK and Lizhu Diagnostics, Zhuhai,
China), anti-HIV1/2 (Biorad, Marnes-la-Coquette, France
and Wantai Diagnostics, Beijing, China), Syphilis (Diasorin
S.P.A.-UK Branch and Lizhu Diagnostics, Zhuhai, China),
respectively [12–14]. Alanine aminotransferase (ALT) level
was quantified with a kinetic method (AusBio Biotech.,
China). Samples HBsAg reactive with both EIAs were
considered confirmed, while samples HBsAg reactive with
a single EIA were re-tested twice by the reactive assay in
duplicate. If the testing was repeatable, the sample was con-
sidered HBsAg positive. Donor samples non-reactive with
serological tests and with normal ALT level were further
screened with the Triplex NAT for HIV-1, HCV and HBV
genomes as previously described [13].
Nucleic acid testing
Detection of viral nucleic acids with NAT was per-
formed using three different modalities: Roche Cobas
Ampliscreen assay (MP24-NAT, Roche Molecular Diag-
nostics, Raritan, USA) was used between January 2005
and January 2006, Kehua real-time PCR assay (MP8-
NAT, Kehua Biotechnology Ldt., Shanghai, China) be-
tween February 2006 and January 2009 and Procleix
Ultrio assay (ID-NAT, Novartis Diagnostics, Emeryville,
USA) between February 2009 and December 2014,
respectively according to manufacturers’ recommenda-
tions. Between January 2005 and January 2009 NAT was
applied to mini-pool of 24 or 8 samples (MP24 or MP8-
NAT) and since February 2009 to individual samples
(ID-NAT). Nucleic acids were extracted from 500 μl of
individual plasma samples. Reactive samples were fur-
ther qualified with the discriminatory assays (COBAS
Monitor Test, in-house PCR or discriminatory Procleix
Wang et al. BMC Infectious Diseases  (2016) 16:498 Page 2 of 9
Ultrio test) for the virus responsible for the signal (HBV,
HCV or HIV-1).
Follow-up testing
Blood donors who tested HBV DNA positive but HBsAg
negative (HBV DNA+/ HBsAg-) were further tested in
1–3 follow-up samples for HBV DNA and serological
markers. Anti-HBs, HBeAg, anti-HBe and anti-HBc were
tested with HBV EIAs (Kehua, Shanghai, China). Anti-
HBs was quantified in IU/L with anti-HBs electrochemi-
luminescence immunoassay (Roche), while HBV DNA
load was quantified in IU/ml by in-house real-time PCR
as previously described [12, 14].
Statistical analyses
SPSS software (version 16.0) was used. Categorical vari-
ables were compared by using Fisher’s exact test. P < 0.05
were considered statistically significant.
Results
Demographic characteristics of blood donors
Between 2005 and 2014, a total of 569,145 candidate
blood donors were recruited and selected by Shenzhen
blood center, Shenzhen, Guangdong, China, from whom
724,700 blood donations were collected from pre-
donation testing qualified donors (Table 1, Fig. 1). The
number of blood donations almost doubled between
2005 and 2014. Of those blood donors, 66.7 % were
male and 33.3 % female, 60.5 % were first-time do-
nors and 39.5 % repeat-donors, respectively. The ratio
between native Guangdongese to donors of other ori-
gins (non-Guangdongese) was 1:2.3, indicating that
migrants from other provinces contributed 70 % of
blood donations. Donor age ranged between 18 and
58 years stratified into 4 age groups of 18–25, 26–35,
36–45 and 46–58 years (Fig. 2). Seventy-six % of
blood donations were collected from young donors
18–25 or 26–35 years.
Prevalence of HBV in blood donor population
Among 569,145 candidate blood donors, 9004 (1.58 %)
were HBsAg positive in pre-donation screening by the
dipstick rapid test, and 4192 (0.75 %) of 560,141 se-
lected donors were further identified as HBsAg react-
ive by EIA after donation. Overall, HBsAg prevalence
was 2.32 % in blood donors over the past 10 years.
Year by year HBsAg prevalence in candidate donors is
presented in Fig. 3a. It follows a U-type curve with,
2.86 % prevalence in 2005 declining to 1.76 % in 2010,
and regularly increasing up to 2.77 % in 2014. When
data is stratified according to donor type (first-time or
repeat), gender or geographical origin (birth place),
the same general curve shape is observed (Fig. 3b, c
and d), suggesting it reflects a general evolution in
China. Prevalence of HBsAg in first-time donors was
significantly higher than in the repeat-donors (Fig. 3b,
P < 0.0001), in male donors than in female donors (Fig,
2c, P = 0.0001), and in native donors than in donors of
other origins (Fig. 2d, P < 0.0001). The incidence of
HBsAg (mean: 0.37 %) in repeat-donors decreased
from 0.6 % in 2005 to 0.16 in 2013 and then
rebounded to 0.38 % in 2014 (Fig. 3b).
HBsAg prevalence was examined in four age groups
(18–25, 26–35, 36–45 and ≥46 years; Table 2). The
overall HBsAg prevalence varied significantly accord-
ing to age (P < 0001). Unexpectedly, the highest
HBsAg prevalence (2.73 %) was found in the youngest
age group (18–25 years), and progressively declined
as age increased to the lowest level (1.71 %) in do-
nors >45 years of age.
Table 1 Demographic characteristics of candidate blood donors between 2005 and 2014 in Shenzhen, China
Year Number of
donors
% of donors in various categories Number of
donationsFirst-time Repeat Male Female Nativea Other originsa
2005 42,638 67.5 32.5 68.1 31.9 27.7 72.3 52,398
2006 44,411 64.6 35.4 69.1 30.9 28.8 71.2 55,117
2007 45,248 50.2 49.8 68.2 31.8 27.4 72.6 58,051
2008 47,086 60.0 40.0 68.5 31.5 26.7 73.3 60,794
2009 48,341 58.8 41.2 68.3 31.7 27.9 72.1 64,496
2010 57,248 62.1 37.9 66.2 33.8 28.4 71.6 73,953
2011 66,232 61.4 38.6 66.2 33.8 30.4 69.6 83,353
2012 73,194 63.8 36.2 66.3 33.7 31.6 68.4 92,033
2013 72,314 56.2 43.8 66.1 33.9 32.2 67.8 92,125
2014 72,433 60.6 39.4 63.4 36.6 33.8 66.2 92,380
Total 569,145 60.5 39.5 66.7 33.3 29.9 70.1 724,700
aAccording to the initial identity card registration that indicates the birth place, blood donors were classified as native born in Guangdong province or of other
origins (born in other provinces of China)
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Prevalence of HBsAg between blood donors born before
and after universal infant vaccination program
implementation
In order to investigate whether the expected impact of
the national neonatal vaccination program implemented
in 1992 in blood donors was confirmed, the presumed
vaccinated and non-vaccinated blood donor populations
were separated according to being born before or after
1992. Blood donors born in 1992 or later who gave
blood between 2010 and 2014 at 18–22 years of age
were considered as vaccinated donors. Blood donors
born before 1992 who gave blood between 2005 and
2013 were considered as non-vaccinated donors giving
blood within the same age range. In first-time donor
population aged 18–22 (Table 3), HBsAg prevalence was
3.61 %. There was a statistically significant difference in
HBsAg prevalence between the populations born <1992
(3.51 %) and born ≥1992 (3.89 %, P = 0.005). In the
population of first-time donors assumed vaccinated
born ≥1992, HBsAg prevalence tended to increase with
age from 3.15 to 4.72 % (P = 0.003–0.0001, 18 v.s. 21 or
22 years). There was no significant difference in
HBsAg prevalence according to age in first-time do-
nors born prior to 1992 (P = 0.228–0.74, 18 v.s. 20, 21
or 22 years). Between assumed vaccinated and non-
vaccinated repeat-donor populations tested at the same
ages (18–22, Table 4), the incidence of HBsAg seroconver-
sion was significantly lower in donors born ≥1992 (0.27 %)
than in those born prior to 1992 (0.57 %, P = 0.008).
Within the population of repeat-donors, the incidence of
HBV infection was found higher at age 22 either born
prior to 1992 (0.55 %) or born ≥1992 (0.32 %) than that at
age 18 born <1992 (0.2 %) or born ≥1992 (<0.01 %),
respectively, but the difference was not statistically signifi-
cant (P > 0.05). Combining first-time and repeat donors
(Tables 3 and 4), the overall HBsAg prevalence calculated
in younger donors aged 18–22 years (3.12 % [3689/
11423]) was higher than in donors aged ≥23 (2.73 %)
(Table 2, P < 0.001).
Yield of HBV DNA positive but HBsAg negative blood
donors
From January 2005 to December 2014, 475,538 sam-
ples with negative HBsAg and normal ALT (<50U/L)
were further tested for HBV DNA by NAT. A total of
144 donations were identified as HBV DNA+/HBAg-,
resulting in a yield of 1:3,302 seronegative blood do-
nors (Table 5). According to follow-up testing results,
106 donors were identified as occult HBV infection
(OBI), 11 as window-period infection (WPI) and 27
unclassified, respectively (Table 5). OBI and WPI fre-
quencies were 1:4,486 and 1:43,231, but 27 HBV DNA
+/HBAg- samples remained unclassified (1:17,613).
OBI carriers were slightly, but not significantly, more
frequent in male (0.020 %) than in female (0.015 %).
Median age was 34 years and had low anti-HBs level
(median 3.9 IU/ml). Viral load (median 23.1 IU/ml) of
OBI samples was low ranging between undetectable
(<10 IU/ml) and 2122 IU/ml. Of 76 HBV DNA+ sam-
ples available for genotyping, 58 samples (76.3 %) were
identified as genotype B and 18 (23.7 %) as genotype
C, respectively.
Fig. 1 Flow chart of blood donor testing. The first part of the study
consisted in retrieving HBsAg screening results for both candidate
donors and selected donors. The second part was the detection of
HBV DNA in HBsAg negative donors
Fig. 2 Distribution of blood donors according to ages. Percentages
(%) of 568,114 blood donors from 2005 to 2014 were distributed
according to population age groups
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Discussion
Shenzhen is a modern city close to Hong Kong, located
in the Eastern part of Guangdong province, south
China. Over 10 millions of people live in Shenzhen,
88.41 % of them being 15–59 years old. According to
age distributions of blood donors, young adults with
ages 18–35 years are the majority of the blood donor
population, who contribute nearly 80 % of blood dona-
tions (Fig. 2). Shenzhen is also a younger city and ap-
proximately 70 % of blood donors are migrant citizens
(Table 1) somewhat reflective of Chinese population as
a whole [15].
In this study, half a million blood donors were
screened for chronic, window period or occult HBV
infections between 2005 and 2014 in Shenzhen, China
(Tables 1 and 4, Figs. 1 and 3). An overall prevalence of
HBsAg in blood donors was 2.9 % in 2005, declined to
1.8 % in 2010, then rebounded to 2.8 % in 2014 during
past 10 years (Fig. 3). Observed HBV prevalence was
significantly higher in first-time donors than in repeat-
donors, in male than in female and in native than in
donors of other origin, respectively (P < 0.0001). As
expected, HBsAg prevalence in first-time donors signifi-
cantly increased with age (Table 2). Low and stable
Fig. 3 Prevalent trends of HBsAg in blood donor populations. a Overall prevalence of HBsAg detected by rapid tests (dipsticks) and EIAs. b HBsAg
prevalence in first-time and repeat donors. c HBsAg prevalence in male and female donors. d HBsAg prevalence in native Guangdongese and
other non-Guangdongese donors. P values were calculated as <0.0001 between the first-time and repeat, male and female, native and other
original donors, respectively
Table 2 HBsAg prevalence according to donor age groups
Age (years) 18–25 26–35 36–45 46–58 Total
Donor type HBsAg+/all % HBsAg+/all % HBsAg+/all % HBsAg+/all % HBsAg+/all %
Male 3904/124,365 3.14 3601/156,658 2.30 1680/77,880 2.16 376/20,922 1.97 9561/379,825 2.52
Female 2015/92,680 2.17 940/56,170 1.67 543/31,383 1.73 137/9087 1.51 3635/189,320 1.92
First-time 5671/160,817 3.53 4218/121,447 3.47 2021/50,851 3.97 450/11,222 4.01 12,360/344,337 3.59
Repeat 248/56,228 0.44 323/91,381 0.35 323/91,381 0.35 63/18,787 0.34 836/224,808 0.38
Native 2567/73,214 3.51 1670/50,584 3.30 835/33,472 2.49 222/13,057 1.70 5294/170,327 3.11
Other origins 3352/143,831 2.33 2871/162,244 1.77 1388/75,791 1.83 291/16,952 1.72 7902/398,818 1.98
Overall 5919/217,045 2.73 4541/212,828 2.13 2223/109,263 2.03 513/30,009 1.71 13,196/569,145 2.32
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prevalence of HBsAg in repeat donors reflected either
new infections occurring between blood donation or
higher sensitivity of assays over time.
The most surprising result in this study was the
higher HBsAg prevalence in assumed vaccinated first-
time donors (3.89 %) aged 18–22 between 2010 and
2014 than in presumed non-vaccinated donors in the
same age range (3.51 %) tested at the same age be-
tween 2005 and 2009 (Table 3, P < 0.005). HBsAg
prevalence in first-time donors born after 1992 tended
to increase with age while in donors born earlier, no
such difference in prevalence according to age was
observed (Table 3). These apparently surprising re-
sults can be interpreted by examining the expected
rate of vertical HBV transmission before 1992 and
after 1992 when compliance was settling in and the
changes in HBV infection in vaccinated Chinese over
the age of 14. Between 1987 and 1992, the rate of
HBV vaccination in China was estimated at 30 % [3,
16]. Assuming a prevalence of HBsAg of 15 % in the
Guangdong province [16] and a 40 % rate of vertical
transmission [17, 18] and 70 % of the population not
vaccinated, the predicted incidence of HBsAg in chil-
dren was 4.3 %, expected to rise somewhat when
these children are tested between age 18 and 22. The
observed HBsAg prevalence in such adults having
become blood donors was 3.5 %, lower than antici-
pated. A possible explanation might be that among the
30 % vaccinated population, HBsAg positive women were
selected for offspring vaccination.
Applying the same calculations to children born in
1992–1996 (blood donors of 18–22) during the ramp up
of vaccination compliance from 30 to 70 %, the expected
HBsAg rate is predicted to decline from 4.25 to 1.8 %
(mean 3.0 %). This estimate is considerably lower than
the 3.9 % observed (Table 3), suggesting that infections
acquired by other means than MTCT played a role. In
two large studies conducted in China and Taiwan, re-
spectively, the prevalence of HBsAg between age 10 and
20–24 progressively increased in presumably or effect-
ively vaccinated general populations from less than 1 %
to approximately 3 % [3, 9]. In the Taiwanese study, evi-
dence of contact with HBV after age 14 when the preva-
lence of anti-HBs has declined below 20 % is provided
by increasing prevalence of HBsAg from 1 to 3 %, anti-
HBc from 2 to 11 % and anti-HBs from 19 to 68 % by
age 24 [9]. This data strongly suggests that protection to
HBV genotype B infection provided by genotype A1
vaccine declines with age and translates into seroconver-
sion to HBsAg and/or anti-HBc or natural anti-HBs
boost when in contact with HBV in a high prevalence of
chronic infection area [12, 19]. The HBsAg prevalence
observed in our study is quite compatible with this
observation. This different distribution might be related
to the progressive decline of anti-HBs vaccine-related
protection leaving these vaccinated donors at higher risk
of infection as they grow older and as previously re-
ported [12]. Other factors may also interfere such as the
type of vaccine utilized (plasma derived or recombinant)
but here are probably insignificant. However, between
Table 3 Prevalence of HBsAg in first-time donors born before and after 1992 tested at the same ages
Age year Born <1992 Born≥ 1992 Overall P value
HBsAg+/total % HBsAg+/total % HBsAg+/total % inter-group
18 152/4600 3.30 162/5151 3.15 314/9751 3.22 0.656
19 373/10,158 3.67 280/8212 3.41 653/18,370 3.55 0.340
20 545/14,797 3.68 253/6029 4.20 798/20,826 3.83 0.080
21 612/17,982 3.40 191/3833 4.98 803/21,815 3.68 0.000
22 692/20,146 3.43 99/2097 4.72 791/22,243 3.56 0.002
All ages 2374/67,683 3.51 985/25,322 3.89 3359/93,005 3.61 0.005
Intra-population of first-time donors, P = 0.228–0.74 from 18 v.s. 20, 21 or 22 years born <1992; P = 0.003–0.0001, 18 v.s. 21, or 22 years born ≥1992
Table 4 Incidence of HBsAg seroconversion in repeat donors born before and after 1992 tested at the same ages
Age year Born <1992 Born≥ 1992 Overall P value
HBsAg+/total % HBsAg+/total % HBsAg+/total % Inter-group
18 1/490 0.20 0/318 <0.01 1/808 0.12 0.606
19 16/2042 0.78 5/1283 0.39 21/3325 0.63 0.163
20 26/4126 0.63 6/1620 0.37 32/5746 0.56 0.234
21 30/5868 0.51 1/1262 0.08 31/7130 0.43 0.034
22 43/7779 0.55 2/630 0.32 45/8409 0.54 0.334
All ages 116/20,305 0.57 14/5113 0.27 130/25,418 0.51 0.008
Intra-population of repeat donors, P = 0.202–0.298 from 18 v.s. 20, 21, or 22 years born <1992; P = 0.341–0.441from 18 v.s. 21 or 22 years born ≥1992
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age 18 and 22, repeat donors presumably vaccinated had
0.3 % incidence of HBV infection, nearly half the rate
observed in older donors, presumably not vaccinated
(Table 4). This incidence of HBsAg seroconversion did
not significantly increase with age (Tables 3 and 4) [12].
This observation is compatible with frequently abortive
infection when vaccinees with low level of anti-HBs are
exposed sexually to high levels of HBV [19]. The contrast
in donors born since 1992 between the high prevalence of
HBsAg and relatively few recent infections suggests
chronic infections being acquired early in life presumably
out of non compliance to vaccination or failure of the
immunization and relatively effective protection against
new infection likely related to sexual activity. In the cohort
of donors born before 1992, it is possible that a fairly high
proportion of them had been vaccinated ahead of the
generalization of the intervention explaining the relatively
low prevalence of chronic HBV infection.
In recent years, occult hepatitis B virus infection (OBI)
attracted considerable attention with regard to blood
safety [5, 20], and was found the major remaining
residual risk of transfusion-transmitted viruses [14, 15].
In Shenzhen blood donor population, the yield of
1:3,302 was detected for HBV DNA+/HBsAg-, included
relatively frequent OBIs (1:3,835) and few cases of
window period infection (1:67,934), although these fre-
quencies might be modified if all yield samples had been
categorized (Table 4). The molecular biological features
of OBIs in blood donors have been well characterized in
East Asia [12–14, 21]. This transfusion risk could be
minimized but not completely eliminated by NAT
screening in blood donation due to insufficient sensitiv-
ity of current assays [6, 7].
Since hepatitis B vaccination became mandatory for all
newborns within 24 h of birth nationwide in 1992, this
universal vaccination program decreased the HBV
prevalence to 1 % in vaccinated children aged <5 years
and led to a reduction of HBV prevalence to 7.2 % in
the general population of China [1]. HBV prevalence
reported from Shenzhen blood donors including vacci-
nated first-time donors is clearly lower than that from
the general Chinese population, but still remains much
higher than expected in vaccinated children. The poten-
tial causes of HBV infection in blood donors, particularly
in vaccinated population may originate from the follow-
ing options [22]. (1) Low level or undetectable anti-HBs.
Previous study confirmed that there is among adequately
vaccinated newborn a small portion (3-7 %) of non- or
low-responders [23]. In addition over 50 % vaccinated
children no longer carry detectable anti-HBs when
reaching 11–17 years [9, 24]. In our previous study of
1494 vaccinated blood donors aged 18–21 years in Shen-
zhen, Southern China, we found approximately 29 % of
donors with no detectable HBV markers and 40 % of
them carrying anti-HBs levels <100 IU/L [12]. Those
vaccinees with low level of anti-HBs are susceptible to
infection associated with breakthrough or leading to oc-
cult HBV infections as described previously [12, 25, 26].
(2) HBV genotype A2 vaccine efficacy. Current hepatitis
B recombinant S protein vaccines are of genotype A2. A
study found that 6 of 9 vaccinated blood donors were
identified as OBIs [19]. Five of these donors had anti-
HBs <100 IU/L and had been infected with non-A2
(genotype B, C, F or D) or mixed HBV strains, which
suggested that protection offered by genotype A2 hepa-
titis B vaccine might not be fully effective for individuals
Table 5 Yield of HBsAg-/HBV DNA+ in blood donorsa
Category OBI WPI Unclassified Overall
Samples 106 11 27 144
Yield 1/4486 1/43,231 1/17,613 1/3302
Gender (F/M) 29/77 5/6 7/20 41/103
Age range (median) 20–56 (34) 19–42 (28) 19–54 (28.5) 19–56 (32)
VL range (median, IU/ml) 0–2122 (23.1) 0–7321 (190.4) 0–2782 (36.4) 0–7321 (27.9)
Anti-HBc+/anti-HBs+/anti-HBe + (%) 2 0 0 2
Anti-HBc+/anti-HBs + (%) 34 0 0 34
Anti-HBc+/anti-HBe + (%) 4 3 0 7
Anti-HBc + only (%) 54 1 0 55
Anti-HBs + only (%) 8 0 0 8
HBeAg + only (%) 0 1 0 1
Anti-HBe + only (%) 0 0 0 0
No seromarker (%) 4 (primary OBI) 6 27 37
aHBV DNA was detected by the NAT from 475,538 blood donors with negative HBsAg and normal ALT level (<50U/L). HBV DNA+/HBsAg- carriers were detected
1–3 times for HBV DNA and sero-markers by the follow-up. The blood samples were detected for HBV DNA+/HBsAg- in follow-up samples were defined as OBIs,
for seroconversion of HBsAg were defined as window period infections (WPIs), while no available of follow-up testing were defined as unclassified that might in-
clude false positive of HBV DNA samples
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exposed to non-A2 strains such as genotype B or C
prevalent in China by close contact with sexual partners
carrying high HBV load. (3) A previous study conducted
in vaccinated blood donors revealed a prevalence of
anti-HBc increasing with age consistent with an increas-
ing cumulative HBV exposure [12], suggesting that those
with low level immune response were insufficiently pro-
tected when in contact with high HBV DNA load mainly
through sexual activity [19]. Many studies showed the
decline and the high percentage of undetectable of
anti-HBs in vaccinated people over 14 years of age, in-
cluding blood donors [9, 12, 27]. A vaccine boost in
adolescents has been considered and its efficacy was
demonstrated [28–30]. However the justification of
such strategy remains controversial and its implemen-
tation still under consideration.
Conclusions
In this study, we observed that the prevalence of HBsAg
was below 2 % in 2010 and rebounded to nearly 3 % in
2014, which might be attributed to a higher incidence of
HBV infection but also to a change of either test
performance or record keeping of donor exclusion with
HBsAg rapid tests. The modest differences in HBsAg
prevalence prior to or since 1992 can be explained by
the slow and progressive increase in vaccination compli-
ance in the Guangdong province. The same study
conducted in blood donors born after 2002 when com-
pliance reached over 90 % might better reflect the
impact of HBV vaccination on the safety of the blood
supply. From a transfusion safety point of view, an HBV
vaccine boost injected between age 15 and 17 years
(prior to starting sexual activity) might be considered to
limit the potential for sexually related new infections.
A powerful clinical trial comparing the incidence of
HBsAg and anti-HBc in young adults having received
or not a vaccine boost around age 14 years would be
highly informative.
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